STOCK TITAN
  1. Home
  2. News
  3. DTIL

Precision BioSciences, Inc. - DTIL STOCK NEWS

Welcome to our dedicated page for Precision BioSciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision BioSciences stock.

Precision BioSciences, Inc., based in Durham, North Carolina, is a pioneering biotechnology company dedicated to enhancing life through advanced genome editing. The company employs its proprietary genome editing platform, ARCUS, to develop innovative product candidates aimed at treating human diseases and offering solutions in food and agriculture.

ARCUS, distinguished by its compact size, enables the delivery of gene edits to a broader range of cells and tissues using both viral and non-viral methods. This versatility makes it a robust tool in Precision BioSciences' mission to address various health conditions and agricultural challenges.

The company has recently made significant strides in its projects, partnering with multiple organizations to expand its research and product development capabilities. These collaborations have been pivotal in propelling forward the potential applications of ARCUS technology.

Precision BioSciences is actively engaged in several cutting-edge projects that underscore its commitment to innovation. The company's financial health is reflected in its consistent investment in research and development, ensuring sustained growth and advancement in its technology.

Latest News:

  • Source: iECURE, Inc.
  • Source: Precision BioSciences, Inc.
  • Source: Precision BioSciences
News

Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

Rhea-AI Summary
Precision BioSciences receives Notice of Allowance for U.S. Patent targeting mutant mitochondrial DNA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
none
-
News

Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments

Rhea-AI Summary
Precision BioSciences highlights new preclinical data for gene editing programs, expands portfolio with potentially curative treatment for mitochondrial myopathy. Virtual R&D Day to be held today. Pipeline updates show potential functional cure for hepatitis B virus and treatment for mitochondrial myopathy. Positive impact on stock price expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
none
-
News

Precision BioSciences to Attend and Present at Upcoming September Investor Conferences

Rhea-AI Summary
Precision BioSciences to participate in investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
conferences
News

Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023

Rhea-AI Summary
Precision BioSciences to host in vivo gene editing R&D Day on September 12, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.89%
Tags
conferences
-
News

Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

Rhea-AI Summary
Precision BioSciences completes deal with Imugene for global rights to azer-cel, extending cash runway through Q3 2025
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
-
News

Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) - FDA advice provides clarity on future development for lead CAR T program candidate Azer-Cel; CAR T partnering discussions ongoing. Preclinical data demonstrating potential of ARCUS for treatment of Duchenne Muscular Dystrophy and Chronic Hepatitis B. Company plans to host In Vivo Gene Editing R&D Day on September 12, 2023. Cash balance provides expected runway through Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
earnings
News

Precision BioSciences to Report Second Quarter Results on August 4, 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.34%
Tags
conferences earnings
-
News

Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day

Rhea-AI Summary
Precision BioSciences has received final meeting minutes from its Type B End of Phase 1 meeting with the FDA for its lead investigational allogeneic CAR T therapy, azercabtagene zapreleucel. The meeting provided clarity and direction on the development of azer-cel, including a potential pathway toward registration. Precision is currently in discussions with potential strategic partners for its cell therapy assets. The company will host an in vivo gene editing R&D Day on September 12, 2023, to provide an update on ARCUS in vivo gene editing candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
partnership
-
News

Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
News

Precision BioSciences to Present at Upcoming June Investor Conferences

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
conferences

FAQ

What is the current stock price of Precision BioSciences (DTIL)?

The current stock price of Precision BioSciences (DTIL) is $4.72 as of December 20, 2024.

What is the market cap of Precision BioSciences (DTIL)?

The market cap of Precision BioSciences (DTIL) is approximately 34.9M.

What does Precision BioSciences, Inc. do?

Precision BioSciences is a biotechnology company that uses its ARCUS genome editing platform to develop treatments for human diseases and provide agricultural solutions.

Where is Precision BioSciences, Inc. located?

The company is based in Durham, North Carolina, United States.

What is ARCUS?

ARCUS is Precision BioSciences' proprietary genome editing platform, known for its small size and ability to deliver gene edits to various cells and tissues.

What are some recent achievements of Precision BioSciences?

The company has advanced its product candidates and formed partnerships to expand its research and development, showcasing the potential of ARCUS technology.

What is the focus of Precision BioSciences' current projects?

The company is focused on developing treatments for human diseases and offering innovative solutions in food and agriculture through its genome editing platform.

How does ARCUS differ from other genome editing tools?

ARCUS is unique due to its relatively small size, which allows it to target a wider range of cells and tissues using both viral and non-viral delivery methods.

Who are some partners of Precision BioSciences?

Precision BioSciences collaborates with organizations like iECURE, Inc. to enhance its research and development capabilities.

What kind of financial strategy does Precision BioSciences employ?

The company consistently invests in research and development to drive growth and technological advancement.

What is the significance of Precision BioSciences' work in agriculture?

The company aims to provide agricultural solutions that can improve food production and sustainability through advanced genome editing.

How does Precision BioSciences contribute to human health?

By developing innovative treatments for various diseases using its ARCUS genome editing platform, Precision BioSciences aims to improve patient outcomes and overall health.

Stock DTIL logo
Precision BioSciences, Inc.

Nasdaq:DTIL

DTIL Rankings

#5066 Ranked by Market Cap
N/A Ranked by Dividends

DTIL Stock Data

34.94M
6.59M
6.58%
44.7%
3.13%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
DURHAM